Trilostane Dose versus Body Weight in the Treatment of Naturally Occurring Pituitary-Dependent Hyperadrenocorticism in Dogs
Article first published online: 18 JUN 2012
Copyright © 2012 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 26, Issue 4, pages 1078–1080, July-August 2012
How to Cite
Feldman, E.C. and Kass, P.H. (2012), Trilostane Dose versus Body Weight in the Treatment of Naturally Occurring Pituitary-Dependent Hyperadrenocorticism in Dogs. Journal of Veterinary Internal Medicine, 26: 1078–1080. doi: 10.1111/j.1939-1676.2012.00956.x
- Issue published online: 13 JUL 2012
- Article first published online: 18 JUN 2012
- Manuscript Accepted: 9 MAY 2012
- Manuscript Revised: 10 APR 2012
- Manuscript Received: 20 DEC 2011
- Birgitta Kulgren
- Ruth Johnston
- Pituitary-dependent hyperadrenocorticism;
Trilostane is commonly used in the treatment of dogs with naturally occurring pituitary-dependent hyperadrenocorticism (PDH). Dose recommendations have varied from the manufacturer and the literature.
As body weight increases, dose/kg or dosage/day of trilostane required to control the clinical signs of PDH decreases.
70 dogs with naturally occurring hyperadrenocorticism.
Retrospective study. Each dog must have been treated for at least 6 months and should have shown a “good response” to trilostane, as determined by owners. Statistical comparisons of dose and dosage were made after the dogs were separated into groups weighing <15 or >15 kg; groups weighing ≤10, 10.1–20, 20.1–30, and ≥30 kg; and then groups based on body surface area versus dose/kg and total amount of trilostane required to control the condition.
There was no significant difference in trilostane dose in mg/kg of body weight or in the total amount of trilostane required daily to control clinical signs, except when the dose for dogs weighing >30 kg was compared with that for the other groups. However, despite lack of statistical significance when comparing groups, there was a significant trend using polynomial regression analysis, suggesting that as body weight increases, the amount of trilostane (mg/kg/dose as well as mg/kg/daily dosage) required to control clinical signs decreases.
Conclusions and Clinical Importance
Dogs weighing >30 kg, and possibly those weighing >15 kg, might require smaller amounts of trilostane per dose or per day than those weighing less, to control PDH-associated clinical signs.